Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
New indication concerns combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations
Findings from the NETTER-2 study
Findings from the NICHE-2 study
Evidence for efficacy is based on the results from the TRANSCEND-MCL study
Findings from NADINA study
New indications concern the treatment of patients with locally advanced or metastatic NSCLC
Findings from the LAURA study
Findings from a pre-specified translational analysis of the MITO END-3 study
Overall survival results from the IMpassion132 study
Evidence for efficacy is based on the results from the TRANSCEND-FL study
Findings from a global study in patients with mCRC harbouring POLE/D1 mutations
Eribulin Baxter is a generic of Halaven, which has been authorised in the EU since 2011
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
